A comparison of iPLEDGE requirements to risk mitigation programs for isotretinoin in other countries and to other teratogenic medications in the United States
J Am Acad Dermatol. 2025 Jan 15:S0190-9622(25)00046-5.
doi: 10.1016/j.jaad.2024.12.039.
Online ahead of print.
1 The George Washington University School of Medicine and Health Sciences, Washington, DC 20052.
2 The George Washington University School of Medicine and Health Sciences, Department of Dermatology, Washington, DC 20052.
3 The George Washington University School of Medicine and Health Sciences, Department of Dermatology, Washington, DC 20052; Children's National Hospital, Division of Dermatology, Washington, DC 20010.